Home >> Healthcare Administration >> Pharmaceuticals >> Food & Beverage >>

Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2013

Published: Feb-2013 | Format: PDF | Global Markets Direct | Number of pages: 106 | Code: MRS - 984

Global Markets Directs, 'Non-Alcoholic Steatohepatitis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis. 

Non-Alcoholic Steatohepatitis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Scope

A snapshot of the global therapeutic scenario for Non-Alcoholic Steatohepatitis.
A review of the Non-Alcoholic Steatohepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Non-Alcoholic Steatohepatitis pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 3
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Non-Alcoholic Steatohepatitis Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Non-Alcoholic Steatohepatitis 8
Non-Alcoholic Steatohepatitis Therapeutics under Development by Companies 10
Non-Alcoholic Steatohepatitis Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Non-Alcoholic Steatohepatitis Therapeutics - Products under Development by Companies 18
Non-Alcoholic Steatohepatitis Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Non-Alcoholic Steatohepatitis Therapeutics Development 21
Isis Pharmaceuticals, Inc. 21
Novo Nordisk A/S 22
Mochida Pharmaceutical Co., Ltd. 23
Genfit 24
Orchid Chemicals & Pharmaceuticals Ltd 25
Immuron Limited 26
Raptor Pharmaceuticals Corp. 27
Phenex Pharmaceuticals AG 28
Wellstat Therapeutics Corporation 29
Conatus Pharmaceuticals Inc. 30
Intercept Pharmaceuticals, Inc. 31
Obio Pharmaceutical Holdings Limited. 32
NasVax Ltd. 33
Stelic Institute & Co. 34
Galmed International Ltd. 35
Connexios Life Sciences Pvt. Ltd. 36
Non-Alcoholic Steatohepatitis - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
GFT-505 - Drug Profile 42
PN-2XXX - Drug Profile 44
RP-103 - Drug Profile 45
G Family Inhibitor For NASH - Drug Profile 47
obeticholic acid - Drug Profile 48
liraglutide - Drug Profile 51
Aramchol - Drug Profile 53
AK-20 - Drug Profile 55
emricasan - Drug Profile 56
metreleptin - Drug Profile 58
pentoxifylline - Drug Profile 59
colesevelam hydrochloride - Drug Profile 60
Anti-aCD3 Mab - Drug Profile 61
GR-MD-02 - Drug Profile 63
RP-104 - Drug Profile 64
IMM-124E - Drug Profile 65
deferasirox - Drug Profile 66
Px-102 - Drug Profile 67
CNXFC-010 - Drug Profile 68
cholecalciferol - Drug Profile 69
levocarnitine - Drug Profile 70
ISIS-DGAT2Rx - Drug Profile 71
icosapent ethyl - Drug Profile 72
BLX-1002 - Drug Profile 73
tranilast - Drug Profile 74
Cymac-001 - Drug Profile 75
AMPK Activators For Fatty Liver Disease - Drug Profile 76
Non-Alcoholic Steatohepatitis Therapeutics - Drug Profile Updates 77
Non-Alcoholic Steatohepatitis Therapeutics - Discontinued Products 94
Non-Alcoholic Steatohepatitis Therapeutics - Dormant Products 95
Non-Alcoholic Steatohepatitis - Product Development Milestones 97
Featured News & Press Releases 97

Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 104
Disclaimer 104

List of Tables

Number of Products Under Development for Non-Alcoholic Steatohepatitis, H1 2013 10
Products under Development for Non-Alcoholic Steatohepatitis - Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Development by Companies, H1 2013 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2013 15
Comparative Analysis by Late Stage Development, H1 2013 16
Comparative Analysis by Mid Clinical Stage Development, H1 2013 17
Comparative Analysis by Early Clinical Stage Development, H1 2013 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Development by Companies, H1 2013 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2013 22
Isis Pharmaceuticals, Inc., H1 2013 23
Novo Nordisk A/S, H1 2013 24
Mochida Pharmaceutical Co., Ltd., H1 2013 25
Genfit, H1 2013 26
Orchid Chemicals & Pharmaceuticals Ltd, H1 2013 27
Immuron Limited, H1 2013 28
Raptor Pharmaceuticals Corp., H1 2013 29
Phenex Pharmaceuticals AG, H1 2013 30
Wellstat Therapeutics Corporation, H1 2013 31
Conatus Pharmaceuticals Inc., H1 2013 32
Intercept Pharmaceuticals, Inc., H1 2013 33
Obio Pharmaceutical Holdings Limited., H1 2013 34
NasVax Ltd., H1 2013 35
Stelic Institute & Co., H1 2013 36
Galmed International Ltd., H1 2013 37
Connexios Life Sciences Pvt. Ltd., H1 2013 38
Assessment by Monotherapy Products, H1 2013 39
Assessment by Stage and Route of Administration, H1 2013 41
Assessment by Stage and Molecule Type, H1 2013 43
Non-Alcoholic Steatohepatitis Therapeutics - Drug Profile Updates 79
Non-Alcoholic Steatohepatitis Therapeutics - Discontinued Products 96
Non-Alcoholic Steatohepatitis Therapeutics - Dormant Products 97
Non-Alcoholic Steatohepatitis Therapeutics - Dormant Products (Contd..1) 98 


List of Figures

Number of Products under Development for Non-Alcoholic Steatohepatitis, H1 2013 10
Products under Development for Non-Alcoholic Steatohepatitis - Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 15
Late Stage Products, H1 2013 16
Mid Clinical Stage Products, H1 2013 17
Early Clinical Stage Products, H1 2013 18
Discovery and Pre-Clinical Stage Products, H1 2013 19
Assessment by Monotherapy Products, H1 2013 39
Assessment by Route of Administration, H1 2013 40
Assessment by Stage and Route of Administration, H1 2013 41
Assessment by Molecule Type, H1 2013 42
Assessment by Stage and Molecule Type, H1 2013 43

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing